Pancreatic Cell News Volume 2.24 | Jun 21 2011

SIRT1 RNAi Knockdown Induces Apoptosis and Senescence, Inhibits Invasion and Enhances Chemosensitivity in Pancreatic Cancer Cells
Researchers investigated the expression of sirtuin 1 (SIRT1) in pancreatic cancer and the effect of SIRT1-targeted RNA interference on cell proliferation and tumor formation in a pancreatic cancer cell line, PANC1. [Gene Ther]

Study Suggests Drug Significantly Improves Glycemic Control in Type 1 Diabetics on Insulin
Results of a small, observational study suggest that liraglutide, an injectable medication used to treat type 2 diabetes, also helps type 1 diabetics on insulin achieve optimal control of their blood glucose levels. [Press release from the University at Buffalo discussing online prepublication in the European Journal of Endocrinology]

DIABETES

Alpha Cells Secrete Acetylcholine as a Non-Neuronal Paracrine Signal Priming Beta Cell Function in Humans
Here researchers show that, in contrast to the case in mouse islets, cholinergic innervation of human islets is sparse. [Nat Med]

The Impact of Hyperglycemia and the Presence of Encapsulated Islets on Oxygenation Within a Bioartificial Pancreas in the Presence of Mesenchymal Stem Cells in a Diabetic Wistar Rat Model
This study investigates the potential of bone marrow versus adipose mesenchymal stem cells to potentiate the oxygenation of encapsulated islets in a subcutaneous bioartificial pancreas. [Biomaterials]

Layer-By-Layer Co-Immobilization of Soluble Complement Receptor 1 and Heparin on Islets
Here, human soluble form complement receptor 1 (sCR1) and heparin were co-immobilized onto the surfaces of islet cells. [Biomaterials]

Islet-Like Cell Aggregates Generated from Human Adipose Tissue Derived Stem Cells Ameliorate Experimental Diabetes in Mice
In the present study, researchers explore the potential of human adipose tissue derived adult stem cells to differentiate into functional islet like cell aggregates. [PLoS One]

Liraglutide as Additional Treatment in Type 1 Diabetes
The objective was to determine whether the addition of liraglutide to insulin in patients with type 1 diabetes leads to an improvement in glycemic control and diminished glycemic variability. [Eur J Endocrinol]

PANCREATIC CANCER

Angiopoietin-2 Drives Lymphatic Metastasis of Pancreatic Cancer
As lymphangiogenesis has been implicated in stimulation of lymphatic metastasis by vascular endothelial growth factor-C (VEGF-C) and VEGF-D, researchers studied the effect of the angioregulatory growth factor angiopoietin-2 on pancreatic ductal adenocarcinoma progression. [FASEB J]

Activated K-ras and INK4a/Arf Deficiency Cooperate During the Development of Pancreatic Cancer by Activation of Notch and NF-κB Signaling Pathways
To assess the molecular mechanism(s) that are involved in the development of pancreatic ductal adenocarcinoma in the compound transgenic mice with activated K-ras and Ink4a/Arf deficiency, researchers used multiple methods, such as Real-time RT-PCR, western blotting assay, immunohistochemistry, MTT assay, invasion, EMSA and ELISA. [PLoS One]

DNA Mismatch Repair Network Gene Polymorphism as a Susceptibility Factor for Pancreatic Cancer
Researchers hypothesized that DNA mismatch repair gene variants are associated with risk of pancreatic cancer. [Mol Carcinog]

Ethanol Differentially Regulates Snail Family of Transcription Factors and Invasion of Premalignant and Malignant Pancreatic Ductal Cells
As ethanol is one of the major causes of pancreatitis, researchers examined the effect of ethanol on Snail family members in immortalized human pancreatic ductal epithelial cells and in pancreatic cancer cells. [J Cell Biochem]

Zealand Pharma and Boehringer Ingelheim Enter into a Licence and Collaboration Agreement to Advance Novel Compounds to Treat Type-2 Diabetes and Obesity
Boehringer Ingelheim obtains global rights to glucagon/GLP-1 dual agonists, including ZP2929, Zealand Pharma’s lead drug candidate in this class. Zealand Pharma is eligible to receive total projected milestone payments of up to €376 million for ZP2929. [Zealand Pharma A/S Press Release]

Nuvilex Anticipates Enhancement of Multi-Drug Cancer Therapies by Inclusion of Encapsulated Cells
Nuvilex, Inc. described potential advantages of cell encapsulation technology for use in cancer therapies when more than one cancer-fighting drug is used. [Nuvilex, Inc. Press Release]

National Institutes of Health (United States)

Food and Drug Administration (United States)
 
Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

National Health Service (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW Screening Stem Cells 2011: From Reprogramming to Regenerative Medicine 
September 26-27, 2011 
Boston, United States

Visit our events page to see a complete list of events in the pancreatic cell community.

Chemist (STEMCELL Technologies) 

Research and Development Senior Technologist (STEMCELL Technologies)

Lab Technologist – Tissue Culture (Maternity Leave) (STEMCELL Technologies) 

Research and Development Technologist, hPSC Media (STEMCELL Technologies) 

Scientist (iPSC) (STEMCELL Technologies)

Post Doctoral Fellow (University of California, Los Angeles)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.